Semaglutide Weight Management and Cardiovascular Risk Reduction

sustainability Purpose and (ESG) Strategic aspirations 2025 • Progress towards zero environmental impact Being respected for adding value to society Being recognised as a sustainable employer ピ Commercial execution Strengthen Diabetes leadership - aim at global value market share of more than 1/3 More than 25 billion DKK in Obesity sales by 2025 Secure a sustained growth outlook for Rare disease CVD: Cardiovascular disease; NASH: Non-alcoholic steatohepatitis; CKD: Chronic kidney disease. Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth. Financials ווון шо Innovation and therapeutic focus • Further raise the innovation-bar for diabetes treatment Develop a leading portfolio of superior treatment solutions for obesity Strengthen and progress the Rare disease pipeline Establish presence in Other serious chronic diseases focusing on CVD, NASH and CKD • Deliver solid sales and operating profit growth . Drive operational efficiencies across the value chain to enable investments in future growth assets • Deliver free cash flow to enable attractive capital allocation to shareholders

View entire presentation